卡培他滨,临床注释-2,变异和临床注释数据

id	等位基因	注释文本
1238	TT	Both variants of rs2297595 are assigned normal function by CPIC. Patients with the TT genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CT or CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.
1237	CT	Both variants of rs2297595 are assigned normal function by CPIC. Patients with the CT genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CC or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.
1236	CC	Both variants of rs2297595 are assigned normal function by CPIC. Patients with the CC genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.

等位基因

注释文本

Both variants of rs2297595 are assigned normal function by CPIC. Patients with the TT genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CT or CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.

1237

Both variants of rs2297595 are assigned normal function by CPIC. Patients with the CT genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CC or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.

1236

Both variants of rs2297595 are assigned normal function by CPIC. Patients with the CC genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.

id	证据的ID	总结
2759	1448124647	Allele C is not associated with increased severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to allele T.
2758	1448124184	Allele C is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to allele T.
2757	1448123099	Allele T is associated with Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms.
2756	1448122697	Allele C is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.
2755	1447945605	Allele C is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to allele T.
2754	1444698729	Genotype CT is associated with increased severity of Drug Toxicity when exposed to capecitabine in people with Colorectal Neoplasms as compared to genotype TT.
2753	827810914	Genotypes CC + CT are associated with increased severity of Diarrhea and hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype TT.
2752	769169640	Genotypes CC + CT are associated with increased severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Breast Neoplasms and gastroesophageal cancer as compared to genotype TT.
2751	1447987449	Genotype CT is not associated with Drug Toxicity when treated with capecitabine, fluorouracil or s 1 (combination) in people with Stomach Neoplasms as compared to genotype TT.
2750	1449161585	Genotypes CT + TT is associated with increased likelihood of hand-foot syndrome, mucositis or Peripheral Nervous System Diseases when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype CC.
2749	PA166109594	Annotation of CPIC Guideline for capecitabine and DPYD
2322	1450371940	Genotypes CC + CT is not associated with risk of Neutropenia when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype TT.
2321	1449732006	Genotypes CC + CT is not associated with Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype TT.
2320	1449162069	Genotypes CC + CT is not associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colonic Neoplasms as compared to genotype TT.
2319	1449161605	Genotype TT is associated with increased severity of Diarrhea when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotypes CC + CT.
2318	1448994748	Allele C is not associated with risk of Drug Toxicity when treated with capecitabine in women with Breast Neoplasms as compared to allele T.
2317	1448262663	Allele C is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.
2316	1448125103	Genotypes CC + CT are not associated with risk of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms and gastroesophageal cancer as compared to genotype TT.
2315	1448124868	Genotypes CC + CT are not associated with severity of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype TT.

证据的ID

总结

2759

1448124647

Allele C is not associated with increased severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to allele T.

2758

1448124184

Allele C is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to allele T.

2757

1448123099

Allele T is associated with Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms.

2756

1448122697

Allele C is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.

2755

1447945605

Allele C is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to allele T.

2754

1444698729

Genotype CT is associated with increased severity of Drug Toxicity when exposed to capecitabine in people with Colorectal Neoplasms as compared to genotype TT.

2753

827810914

Genotypes CC + CT are associated with increased severity of Diarrhea and hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype TT.

2752

769169640

Genotypes CC + CT are associated with increased severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Breast Neoplasms and gastroesophageal cancer as compared to genotype TT.

2751

1447987449

Genotype CT is not associated with Drug Toxicity when treated with capecitabine, fluorouracil or s 1 (combination) in people with Stomach Neoplasms as compared to genotype TT.

2750

1449161585

Genotypes CT + TT is associated with increased likelihood of hand-foot syndrome, mucositis or Peripheral Nervous System Diseases when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype CC.

2749

PA166109594

Annotation of CPIC Guideline for capecitabine and DPYD

2322

1450371940

Genotypes CC + CT is not associated with risk of Neutropenia when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype TT.

2321

1449732006

Genotypes CC + CT is not associated with Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype TT.

2320

1449162069

Genotypes CC + CT is not associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colonic Neoplasms as compared to genotype TT.

2319

1449161605

Genotype TT is associated with increased severity of Diarrhea when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotypes CC + CT.

2318

1448994748

Allele C is not associated with risk of Drug Toxicity when treated with capecitabine in women with Breast Neoplasms as compared to allele T.

2317

1448262663

Allele C is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.

2316

1448125103

Genotypes CC + CT are not associated with risk of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms and gastroesophageal cancer as compared to genotype TT.

2315

1448124868

Genotypes CC + CT are not associated with severity of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype TT.

id	类型	评论
1366	Update	CA score added as part of scoring system release. LOE assigned following curator review.
1365	Update	Added CPIC function and modified text.
1364	Update	Attached CPIC guideline and removed override.
1363	Create	Created

类型

1366

Update

CA score added as part of scoring system release. LOE assigned following curator review.

1365

Update

Added CPIC function and modified text.

1364

Update

Attached CPIC guideline and removed override.

1363

Create